Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 113Urinary Bladder Neoplasms 56Carcinoma, Non-Small-Cell Lung 52Cholangiocarcinoma 33Biliary Tract Neoplasms 32Neoplasm Metastasis 30Ovarian Neoplasms 27Lymphoma, Large B-Cell, Diffuse 26Breast Neoplasms 25Lung Neoplasms 24Neoplasms 23Carcinoma, Transitional Cell 23Triple Negative Breast Neoplasms 22Nasopharyngeal Carcinoma 21Colorectal Neoplasms 20Recurrence 17Non-Muscle Invasive Bladder Neoplasms 16Gallbladder Neoplasms 15Fallopian Tube Neoplasms 15Sarcoma 13Bile Duct Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Hodgkin Disease 10Lymphoma 9Uterine Cervical Neoplasms 8Adenocarcinoma 8Stomach Neoplasms 7Lymphoma, Non-Hodgkin 7Endometrial Neoplasms 7Nasopharyngeal Neoplasms 6

Interventions

Taxes 1Hydroxychloroquine 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Untreated Resectable Pancreatic Adenocarcinoma × Gemcitabine × 1 year × Clear all
NCT04669197 2025-08-15

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer

HonorHealth Research Institute

Phase 2 Active not recruiting
19 enrolled
Gastrointestinal

Untreated Resectable Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡